Recently, Lin et al. conducted a phase I study with a 3+3 design to evaluate the safety and efficacy of CAR T cells targeting GD2, modified with a constitutively active interleukin-7 receptor (C7R-GD2.CARTs), in the treatment of DMG with H3K27 alterations and other recurrent pediatric CNS tumors expressing GD2. This evidence concerns the gene IL7R and central nervous system neoplasm.